Nucleic Acid Drug Delivery Technologies: Players, products & prospects to 2015

Table of Contents

Executive Summary

• Competitor Ratio Analysis Summary

Introduction

Overview of delivery technologies for genetic material: past, prese nt & future

• Nucleic acid delivery: motivators & resistors
  • Motivators
  • Resistors

NUCLEIC ACID DELIVERY TECHNOLOGIES

• Types of nucleic acid based products under development by the pharma industry
  • Viral vector delivery of nucleic acids
    • Figure 1: Schematic of gene therapy utilising an AAV vector
    • Figure 2: Schematic of gene therapy utilising HVJ envelope - virosome
  • Non-viral vector delivery of nucleic acids
    • Figure 3: Stable nucleic acid-lipid particles
    • Figure 4: Targeted nanoparticles
    • Figure 5: Schematic of Macroflux Technology
    • Figure 6: Schematic of PMED Technology and delivery
    • Table 1: Advantages and disadvantages of nucleic acid platforms
• Current therapeutic applications for the viral and non-viral delivery of nucleic acids
• Leading nucleic acid based products in development
  • Table 2: Nucleic acid-based approved/filed drugs
  • Table 3: Selection of nucleic acid-based developmental drugs
• Future commercial applications & opportunities

STRAT EGIES OF DRUG DELIVERY COMPANIES

• Leading nucleic acid drug delivery companies
  • Table 4: Leading nucleic acid drug delivery specialists
• Partnerships & acquisitions
  • Strategic developmental & commercialisation partnerships
  • Mergers & acquisitions
    • Table 5: Recent partnerships & acquisitions in the nucleic acid field
• Intellectual Property
  • Table 6: Nucleic acid patents

THE viral and non-viral vector Delivery MARKET

• Now 2007
  • Table 7: Approved nucleic acid product sales
• Future 2015
  • Table 8: Global controlled-release product sales
  • Table 9: Novel nucleic acid product sales

COMPETITOR ANALYSIS

• Movers & Shakers: Cutting edge or losing their grip
  • Table 10: Movers & shakers in nucleic acid drug delivery systems

COMPANY PROFILES

• AlphaVax, Inc.
  • Figure 7: The alphavaccine platform system
  • Table 11: AlphaVax product pipeline
  • Table 12: AlphaVax' sales forecasts (US$ million)
• Altea Therapeutics, Inc.)
  • Table 13: Altea Therapeutics' product pipeline
• AP Pharma, Inc
  • Table 14: AP Pharma' s product pipeline
• Aradigm, Inc
  • Table 15: Aradigm' s product pipeline
• BioDelivery Sciences International
  • Figure 8: Bioral Technology
  • Figure 9: Direct membrane fusion
  • Table 16: BDSI' s product pipeline
• Calando Pharmaceuticals
  • Figure 10: Schematic of cyclodextrin polymeric nanoparticles
  • Table 17: Calando' s product pipeline
  • Table 18: Calando' s sales forecasts
• Copernicus Therapeutics
  • Figure 11: Uptake and trafficking of condensed nanoparticle DNA
  • Table 19: Copernicus' product pipeline
  • Table 20: Copernicus' sales forecasts
• Diatos SA
  • Table 21: Diatos' product pipeline
• DOR BioPharma, Inc
  • Table 22: DOR' s product pipeline
• Expression Genetics, Inc
  • Figure 12: TheraPlas Technology Platform
  • Table 23: EGEN' s product pipeline
  • Table 24: EGEN' s sales forecasts
• Inovio Biomedical Corporation
  • Figure 13: Inovio' s gene delivery platform
  • Table 25: Inovio' s product pipeline
  • Table 26: Inovio' s sales forecasts
• Macroflux Corporation
  • Table 27: Macroflux' product pipeline
• Maxcyte, Inc
  • Figure 14: MaxCyte' s GT ex-vivo cell loading system
  • Table 28: MaxCyte' s product pipeline
• Mirus Bio Corporation
  • Figure 15: PolyConjugates - siRNA delivery system
  • Table 29: Mirus' product pipeline
  • Table 30: Mirus' sales forecasts
• Nanotherapeutics Inc.
  • Table 31: Nanotherapeutics' product pipeline
• NeoPharm
  • Table 32: NeoPharm' s product pipeline
• Novagali Pharma SA
  • Table 33: Novagali' s product pipeline
• PCI Biotech
  • Table 34: PCI' s product pipeline
• PowderMed Inc
  • Table 35: PowderMed' s product pipeline
  • Table 5.2.25: PowderMed' s sales forecasts
• Protiva Biotherapeutics, Inc
  • Table 37: Protiva' s product pipeline
  • Table 38: Protiva' s sales forecasts
• Silence Therapeutics plc
  • Table 39: Silence Therapeutics' product pipeline
  • Table 40: Silence Therapeutics' sales forecasts
• Supratek Pharma Inc.
  • Table 40: Supratek' s product pipeline
• Tekmira Pharmaceuticals Corporation
  • Table 42: Tekmira' s product pipeline
  • Table 43: Tekmira' s sales forecasts
• Vical Inc.
  • Table 44: Vical' s product pipeline
  • Table 45: Vical' s sales forecasts

APENDIX 1

• Table 46: Global nucleic acid approved drugs sales 2006A-20015E

APPENDIX 2

• Table 47: Global nucleic acid developmental drugs sales 2006A-20015E

APENDIX 3

• Competitor Ratio Analysis Criteria
• Table 48: Key nucleic acid delivery companies by 2015

BIBLIOGRAPHY

GLOSSARY

ACRONYMS

FOOTNOTE REFERENCES